Login / Signup

Thrombocytosis with acquired von Willebrand disease in an adolescent with sickle cell disease.

Marianne E McPherson YeeGlaivy BatsuliSatheesh ChonatSunita Park
Published in: Clinical case reports (2020)
Thrombocytosis is common in sickle cell disease and may contribute to vaso-occlusion. Hydroxyurea treats extreme thrombocytosis. Acquired von Willebrand disease should be considered prior to aspirin therapy.
Keyphrases
  • sickle cell disease
  • low dose
  • young adults
  • mental health
  • climate change
  • type diabetes
  • cardiovascular disease
  • cardiovascular events
  • stem cells
  • coronary artery disease
  • mesenchymal stem cells
  • replacement therapy